AXIM Biotechnologies Inc.

AXIM Biotechnologies Inc.

AXIM® Biotechnologies, Inc. (AXIM) is a world leader in research and development of cannabinoid-based pharmaceutical products.
Biotechnology
1d 5d 1m 6m 1y Max

AXIM Biotechnologies Inc. News

25 Jun

AXIM® Biotechnologies Signs Supply Agreement to Register Cannabinoid Oral Care Products in Clinical Trials

NEW YORK, June 25, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and development, today.

05 Jun

FOX Business Features Opinion Article Authored by AXIM Biotechnologies, Inc. CEO on Why Legal CBD is Good f

AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has garnered news coverage for an...

03 Jun

AXIM® Biotechnologies, Inc. Signs Cannabinoid Product Supply Agreement with Healthcare Company for Clinical

AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has signed a cannabinoid product supply...

15 May

AXIM® Biotechnologies Announces Additional Purchase Order for Nutraceutical Product With Leading Direct Sel

NEW YORK, May 15, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech”, “AXIM”, or the “Company”), a world leader in cannabinoid research and development, today.

14 May

AXIM® Biotechnologies to Present at Cannastocks 2019 Q1 Conference

AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech”, “Axim”, or the “Company”), a world leader in cannabinoid research and development, today announced that the Company will be attending and presenting...

29 Apr

Don't Be Fooled by This Marijuana Penny Stock -- It's Bad News

Dig beneath its rapid sales growth, and you'll find good reason why this pot stock is down 19% since the year began.

23 Apr

AXIM® Biotechnologies, Inc. Nutraceutical Division Receives Purchase Order for 50,000 Boxes of the Company’

NEW YORK, April 23, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today.

12 Apr

AXIM® Biotechnologies, Inc. Announces Attendance and Presentation by Chief Technology Officer Lekhram Chang

NEW YORK, April 12, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today.

09 Apr

AXIM® Biotech Enters Services Agreement With CRO to Begin Clinical Studies On Dronabinol and CBD Chewing Gu

AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with...

04 Apr

AXIM® Biotechnologies, Inc. Appoints Mauricio Javier Gatto-Bellora to Company’s Board of Directors

AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (AXIM), a world leader in cannabinoid research and development, today announced the appointment of Mauricio Javier Gatto-Bellora to...

Load more

About AXIM Biotechnologies Inc.

We were incorporated in the state of Nevada on November 18, 2010, as AXIM International, Inc. On July 24, 2014, we changed our name to AXIM Biotechnologies, Inc. to better reflect our current, expanded business operations. In early 2014, we discontinued our organic waste marketable by-product business to focus on our anticipated new business to become an innovative biotechnology company working on the treatment of pain, spasticity, anxiety, and other medical disorders with the application of known and novel cannabinoid-based products. Our focus is also on research, development and production of pharmaceutical, nutraceutical and cosmetic products.

AXIM is developing broad IP portfolio covering diverse aspects of both technology and clinical indications. Clinical development programs cover diverse indications including diseases with currently unmet or poorly met treatment needs and providing solutions with potentially significantly reduced side effects to the currently available ones.

Team

John W. Huemoeller I...
Chief Executive Officer
Dr. George E. Anasta...
Founder | Chairman of the Board
Dr. Philip A. Van Da...
Chief Medical Officer
Lekhram Changoer
Chief Technology Officer
Prof. Renger Witkamp
Professor
John Zajicek
Professor
Dr. Arno Hazekamp
Advisor
Dr. Robert Ritch
Professor
Dr. Ilya Reznik
Dr. Jacques F. Meis
Dr. Donald Abrams
$ 0.45
1.12%
Open:
0.45
High:
0.45
Low:
0.44
Symbol:
AXIM